{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:37:10Z","timestamp":1784547430449,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The therapeutic value of immune checkpoint inhibitors (ICIs) in a variety of tumors has been found and recognized, and although ICIs have improved the prognosis of many patients with advanced tumors, these drugs sometimes cause immune-related adverse events (irAEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 67-year-old woman with advanced rectal endocrine tumor. Ten days after receiving two cycles of treatment with camrelizumab combined with http:\/\/www.baidu.com\/link?url=shAWG4LYTwwBcZAEb6pLb6DkDndJR2tUgOfFiWAkOf0hS-_sj2jjSLBwYaxSiHY3r6yPj31Lp2DCP-7q3w7ho5HIV46V4fbIShFyUY7Cbka sorafenib, the patient suddenly suffered from chest tightness, shortness of breath and progressive aggravation of limb weakness, the high-sensitivity cardiac troponin T (hs-cTnT) was elevated to 3015pg\/mL and N-terminal pro-B-type natriuretic peptide (NT-proBNP) up to 5671pg\/mL, and creatine kinase (CK) was 1419U\/L.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis and Interventions:<\/jats:title>\n            <jats:p>The patient was diagnosed as immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome. The patient was transferred to the intensive care unit (ICU) in time and given oxygen inhalation, glucocorticoids, immunoglobulin and anticholinesterase drugs, and other related treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 2 weeks, the symptoms of myasthenia gravis (MG) were relieved, and the level of myocardial injury markers decreased significantly, but it was still at a high level. The patient's family refused further treatment, and the patient died soon after.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>In this paper, Through the report and follow-up analysis of this case, this paper recognizes that the early correct understanding and evaluation of this fulminant and fatal irAEs and the reasonable treatment of patients are very important for the prognosis of patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032240","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:37:59Z","timestamp":1673559479000},"page":"e32240","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-0986","authenticated-orcid":false,"given":"Loulu","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Weifang Medical University, Weifang, China"},{"name":"Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"},{"name":"School of Graduate, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-18-3858","article-title":"Biomarkers for immunotherapy toxicity: are cytokines the answer?.","volume":"25","author":"Johnson","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R4-20250504","first-page":"54","article-title":"Immune checkpoint inhibitor-related myocarditis: recognition, surveillance, and management.","volume":"26","author":"Kuhnly","year":"2022","journal-title":"Clin J Oncol Nurs"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?.","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors.","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e001293","DOI":"10.1136\/jitc-2020-001293","article-title":"PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction.","volume":"8","author":"Xia","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit.","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2021.07.023","article-title":"Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.","volume":"157","author":"Liu","year":"2021","journal-title":"Eur J Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.","volume":"7","author":"Safa","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors.","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.03.006","article-title":"Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis.","volume":"113","author":"Tedbirt","year":"2019","journal-title":"Eur J Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors.","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management.","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment.","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e018306","DOI":"10.1161\/JAHA.120.018306","article-title":"Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis.","volume":"9","author":"Drobni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.","volume":"8","author":"Cautela","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases.","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist.","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies.","volume":"23","author":"Stein-Merlob","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41569-019-0164-7","article-title":"T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.","volume":"16","author":"Simons","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?.","volume":"19","author":"Dhawan","year":"2015","journal-title":"Neurologist"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:47:37Z","timestamp":1746334057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":24,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032240","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}